Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA
Autores principales: Rosenstock, Julio, Perkovic, Vlado, Johansen, Odd Erik, Cooper, Mark E., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Pencina, Michael, Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Woerle, Hans Juergen, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583576/
https://ncbi.nlm.nih.gov/pubmed/30418475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.18269
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares